Related Experiment Video

Updated: May 6, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

668

Reversible posterior leukoencephalopathy syndrome induced by axitinib

Antonin Levy1, Lyes Benmoussa1, Samy Ammari2

  • 1Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France.

Clinical Genitourinary Cancer
|October 19, 2013
PubMed
Abstract

No abstract available in PubMed .

Keywords:
AxitinibClear-cell renal adenocarcinomaReversible posterior leukoencephalopathy syndromeSide-effectVascular endothelial growth factor

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Experiment Videos

Last Updated: May 6, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

668
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K

Articles linked to this work by shared authors, journal, and citation graph.

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.

Current treatment options in oncology·2026

RAS signaling at the crossroads of radioresistance and tumor immunity.

Journal for immunotherapy of cancer·2026

Redefining Radiotherapy: The Gut as an Active Target in Immuno-oncology.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2026

Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.

The Lancet. Oncology·2026

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

JAMA oncology·2026

Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications-A Systematic Review.

Clinical genitourinary cancer·2026

Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.

Clinical genitourinary cancer·2026

GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy.

Clinical genitourinary cancer·2026

The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer.

Clinical genitourinary cancer·2026

Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry.

Clinical genitourinary cancer·2026

PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis.

Clinical genitourinary cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us